Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT)

Mahmoud Aljurf, Amr Nassar, Amir Ali Hamidieh, Alaa Elhaddad, Rose Marie Hamladji, Ali Bazarbachi, Ahmed Ibrahim, Tarek Ben Othman, Fawzi Abdel-Rahman, Amal Alseraihy, Omar Fahmy, Ayad Ahmed Hussein, Abdulaziz Alabdulaaly, Salman Adil, Salam Salim Amur Alkindi, Mohamed Bayoumy, David Dennison, Mohamed Amine Bekadja, Ahmed Nacer Redhouane, Walid RasheedAhmed Alsagheir, Reem Alsudairy, Saloua Ladeb, Said Benchekroun, Mani Ramzi, Parvez Ahmed, Hassan Elsolh, Syed Osman Ahmed, Fazal Hussain, Ardeshir Ghavamzadeh

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective/Background The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) group has accumulated over 31 years of data and experience in hematopoietic stem cell transplantation (HSCT), particularly in hemoglobinopathies, severe aplastic anemia, inherited metabolic and immune disorders, in addition to a wide array of hematologic malignancies unique to this region. A regional update in current HSCT trends is highly warranted. We studied the trends of HSCT activities in World Health Organization-Eastern Mediterranean (EMRO) region, surveyed by the EMBMT, between 2011 and 2012. Methods Retrospective analysis of the survey data mainly of cumulative number of transplants, types of transplants (autologous vs. allogeneic), types of conditioning such as myeloablative versus reduced intensity was conducted. Also, trends in leukemias, hemoglobinopathies, severe aplastic anemia, inherited bone marrow failure syndromes, amongst others were analyzed. Results Twenty-one teams from nine EMRO countries reported their data (100% return rate) to the EMBMT for the years 2011-2012, with a total of 3,546 first HSCT (1,670 in 2011; 1,876 in 2012). Allogeneic HSCT (allo-HSCT) represented the majority (62%) in both years. The main indications for allo-HSCT were acute leukemias (988; 46%), bone marrow failure syndromes (421, 20%), hemoglobinopathies (242; 11%), and immune deficiencies (157; 7%). There was a progressive increase in the proportions of chronic myeloid leukemia cases transplanted beyond first chronic phase (37 [7%] of all chronic myeloid leukemia cases in 2011 vs. 39 [29%] in 2012). The main indications for autologous transplants were multiple myeloma/plasma cell disorders (510; 39%), Hodgkin lymphoma (311; 24%), non-Hodgkin lymphoma (259; 20%), and solid tumors (163; 12%). Reduced intensity conditioning continued to show a progressive decrease over years (9.5% in 2011 vs. 7.9% in 2012), yet remained relatively low compared with contemporary practices in Europe published by EBMT. The vast majority (91%) of allo-HSCT source was from sibling donors with continued dominance of peripheral blood (64%) followed by bone marrow (33%).While umbilical cord blood transplants increased to 4% of allo-HSCT, matched unrelated donor remained underutilized and there was no haplo-identical transplant reported. Large centers with >50 HSCT/year, showed a continued increase in the total number of allo-HSCT over the past 2 years that may be related to capacity building issues and require further studies. Conclusion There is a discernable increase of HSCT rate in the EMRO region with a significant expansion in utilization of cord blood transplants and allogeneic peripheral blood-HSCT as a valuable source. However, further research of outcome data and the development of regional donor banks (cord blood and matched unrelated donors) may help to facilitate future planning to satisfy the escalating regional needs and augment collaboration within the EMBMT and globally.

Original languageEnglish
Pages (from-to)167-175
Number of pages9
JournalHematology/ Oncology and Stem Cell Therapy
Volume8
Issue number4
DOIs
Publication statusPublished - 2015

Fingerprint

Mediterranean Region
Hematopoietic Stem Cell Transplantation
Transplantation
Bone Marrow
Hemoglobinopathies
Fetal Blood
Transplants
Unrelated Donors
Aplastic Anemia
Autografts
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia
Tissue Donors
Capacity Building
Peripheral Blood Stem Cell Transplantation
Immune System Diseases
Hematologic Neoplasms
Plasma Cells
Multiple Myeloma
Hodgkin Disease

Keywords

  • Conditioning
  • EMRO
  • Hematopoietic stem cell transplantation
  • Stem cell source

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012 : A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT). / Aljurf, Mahmoud; Nassar, Amr; Hamidieh, Amir Ali; Elhaddad, Alaa; Hamladji, Rose Marie; Bazarbachi, Ali; Ibrahim, Ahmed; Ben Othman, Tarek; Abdel-Rahman, Fawzi; Alseraihy, Amal; Fahmy, Omar; Hussein, Ayad Ahmed; Alabdulaaly, Abdulaziz; Adil, Salman; Alkindi, Salam Salim Amur; Bayoumy, Mohamed; Dennison, David; Bekadja, Mohamed Amine; Redhouane, Ahmed Nacer; Rasheed, Walid; Alsagheir, Ahmed; Alsudairy, Reem; Ladeb, Saloua; Benchekroun, Said; Ramzi, Mani; Ahmed, Parvez; Elsolh, Hassan; Ahmed, Syed Osman; Hussain, Fazal; Ghavamzadeh, Ardeshir.

In: Hematology/ Oncology and Stem Cell Therapy, Vol. 8, No. 4, 2015, p. 167-175.

Research output: Contribution to journalArticle

Aljurf, M, Nassar, A, Hamidieh, AA, Elhaddad, A, Hamladji, RM, Bazarbachi, A, Ibrahim, A, Ben Othman, T, Abdel-Rahman, F, Alseraihy, A, Fahmy, O, Hussein, AA, Alabdulaaly, A, Adil, S, Alkindi, SSA, Bayoumy, M, Dennison, D, Bekadja, MA, Redhouane, AN, Rasheed, W, Alsagheir, A, Alsudairy, R, Ladeb, S, Benchekroun, S, Ramzi, M, Ahmed, P, Elsolh, H, Ahmed, SO, Hussain, F & Ghavamzadeh, A 2015, 'Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT)', Hematology/ Oncology and Stem Cell Therapy, vol. 8, no. 4, pp. 167-175. https://doi.org/10.1016/j.hemonc.2015.09.002
Aljurf, Mahmoud ; Nassar, Amr ; Hamidieh, Amir Ali ; Elhaddad, Alaa ; Hamladji, Rose Marie ; Bazarbachi, Ali ; Ibrahim, Ahmed ; Ben Othman, Tarek ; Abdel-Rahman, Fawzi ; Alseraihy, Amal ; Fahmy, Omar ; Hussein, Ayad Ahmed ; Alabdulaaly, Abdulaziz ; Adil, Salman ; Alkindi, Salam Salim Amur ; Bayoumy, Mohamed ; Dennison, David ; Bekadja, Mohamed Amine ; Redhouane, Ahmed Nacer ; Rasheed, Walid ; Alsagheir, Ahmed ; Alsudairy, Reem ; Ladeb, Saloua ; Benchekroun, Said ; Ramzi, Mani ; Ahmed, Parvez ; Elsolh, Hassan ; Ahmed, Syed Osman ; Hussain, Fazal ; Ghavamzadeh, Ardeshir. / Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012 : A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT). In: Hematology/ Oncology and Stem Cell Therapy. 2015 ; Vol. 8, No. 4. pp. 167-175.
@article{fd18c7402ba44008becb58d9871b65fc,
title = "Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012: A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT)",
abstract = "Objective/Background The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) group has accumulated over 31 years of data and experience in hematopoietic stem cell transplantation (HSCT), particularly in hemoglobinopathies, severe aplastic anemia, inherited metabolic and immune disorders, in addition to a wide array of hematologic malignancies unique to this region. A regional update in current HSCT trends is highly warranted. We studied the trends of HSCT activities in World Health Organization-Eastern Mediterranean (EMRO) region, surveyed by the EMBMT, between 2011 and 2012. Methods Retrospective analysis of the survey data mainly of cumulative number of transplants, types of transplants (autologous vs. allogeneic), types of conditioning such as myeloablative versus reduced intensity was conducted. Also, trends in leukemias, hemoglobinopathies, severe aplastic anemia, inherited bone marrow failure syndromes, amongst others were analyzed. Results Twenty-one teams from nine EMRO countries reported their data (100{\%} return rate) to the EMBMT for the years 2011-2012, with a total of 3,546 first HSCT (1,670 in 2011; 1,876 in 2012). Allogeneic HSCT (allo-HSCT) represented the majority (62{\%}) in both years. The main indications for allo-HSCT were acute leukemias (988; 46{\%}), bone marrow failure syndromes (421, 20{\%}), hemoglobinopathies (242; 11{\%}), and immune deficiencies (157; 7{\%}). There was a progressive increase in the proportions of chronic myeloid leukemia cases transplanted beyond first chronic phase (37 [7{\%}] of all chronic myeloid leukemia cases in 2011 vs. 39 [29{\%}] in 2012). The main indications for autologous transplants were multiple myeloma/plasma cell disorders (510; 39{\%}), Hodgkin lymphoma (311; 24{\%}), non-Hodgkin lymphoma (259; 20{\%}), and solid tumors (163; 12{\%}). Reduced intensity conditioning continued to show a progressive decrease over years (9.5{\%} in 2011 vs. 7.9{\%} in 2012), yet remained relatively low compared with contemporary practices in Europe published by EBMT. The vast majority (91{\%}) of allo-HSCT source was from sibling donors with continued dominance of peripheral blood (64{\%}) followed by bone marrow (33{\%}).While umbilical cord blood transplants increased to 4{\%} of allo-HSCT, matched unrelated donor remained underutilized and there was no haplo-identical transplant reported. Large centers with >50 HSCT/year, showed a continued increase in the total number of allo-HSCT over the past 2 years that may be related to capacity building issues and require further studies. Conclusion There is a discernable increase of HSCT rate in the EMRO region with a significant expansion in utilization of cord blood transplants and allogeneic peripheral blood-HSCT as a valuable source. However, further research of outcome data and the development of regional donor banks (cord blood and matched unrelated donors) may help to facilitate future planning to satisfy the escalating regional needs and augment collaboration within the EMBMT and globally.",
keywords = "Conditioning, EMRO, Hematopoietic stem cell transplantation, Stem cell source",
author = "Mahmoud Aljurf and Amr Nassar and Hamidieh, {Amir Ali} and Alaa Elhaddad and Hamladji, {Rose Marie} and Ali Bazarbachi and Ahmed Ibrahim and {Ben Othman}, Tarek and Fawzi Abdel-Rahman and Amal Alseraihy and Omar Fahmy and Hussein, {Ayad Ahmed} and Abdulaziz Alabdulaaly and Salman Adil and Alkindi, {Salam Salim Amur} and Mohamed Bayoumy and David Dennison and Bekadja, {Mohamed Amine} and Redhouane, {Ahmed Nacer} and Walid Rasheed and Ahmed Alsagheir and Reem Alsudairy and Saloua Ladeb and Said Benchekroun and Mani Ramzi and Parvez Ahmed and Hassan Elsolh and Ahmed, {Syed Osman} and Fazal Hussain and Ardeshir Ghavamzadeh",
year = "2015",
doi = "10.1016/j.hemonc.2015.09.002",
language = "English",
volume = "8",
pages = "167--175",
journal = "Hematology/ Oncology and Stem Cell Therapy",
issn = "1658-3876",
publisher = "King Faisal Specialist Hospital and Research Centre",
number = "4",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation in the Eastern Mediterranean Region (EMRO) 2011-2012

T2 - A comprehensive report on behalf of the Eastern Mediterranean Blood and Marrow Transplantation group (EMBMT)

AU - Aljurf, Mahmoud

AU - Nassar, Amr

AU - Hamidieh, Amir Ali

AU - Elhaddad, Alaa

AU - Hamladji, Rose Marie

AU - Bazarbachi, Ali

AU - Ibrahim, Ahmed

AU - Ben Othman, Tarek

AU - Abdel-Rahman, Fawzi

AU - Alseraihy, Amal

AU - Fahmy, Omar

AU - Hussein, Ayad Ahmed

AU - Alabdulaaly, Abdulaziz

AU - Adil, Salman

AU - Alkindi, Salam Salim Amur

AU - Bayoumy, Mohamed

AU - Dennison, David

AU - Bekadja, Mohamed Amine

AU - Redhouane, Ahmed Nacer

AU - Rasheed, Walid

AU - Alsagheir, Ahmed

AU - Alsudairy, Reem

AU - Ladeb, Saloua

AU - Benchekroun, Said

AU - Ramzi, Mani

AU - Ahmed, Parvez

AU - Elsolh, Hassan

AU - Ahmed, Syed Osman

AU - Hussain, Fazal

AU - Ghavamzadeh, Ardeshir

PY - 2015

Y1 - 2015

N2 - Objective/Background The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) group has accumulated over 31 years of data and experience in hematopoietic stem cell transplantation (HSCT), particularly in hemoglobinopathies, severe aplastic anemia, inherited metabolic and immune disorders, in addition to a wide array of hematologic malignancies unique to this region. A regional update in current HSCT trends is highly warranted. We studied the trends of HSCT activities in World Health Organization-Eastern Mediterranean (EMRO) region, surveyed by the EMBMT, between 2011 and 2012. Methods Retrospective analysis of the survey data mainly of cumulative number of transplants, types of transplants (autologous vs. allogeneic), types of conditioning such as myeloablative versus reduced intensity was conducted. Also, trends in leukemias, hemoglobinopathies, severe aplastic anemia, inherited bone marrow failure syndromes, amongst others were analyzed. Results Twenty-one teams from nine EMRO countries reported their data (100% return rate) to the EMBMT for the years 2011-2012, with a total of 3,546 first HSCT (1,670 in 2011; 1,876 in 2012). Allogeneic HSCT (allo-HSCT) represented the majority (62%) in both years. The main indications for allo-HSCT were acute leukemias (988; 46%), bone marrow failure syndromes (421, 20%), hemoglobinopathies (242; 11%), and immune deficiencies (157; 7%). There was a progressive increase in the proportions of chronic myeloid leukemia cases transplanted beyond first chronic phase (37 [7%] of all chronic myeloid leukemia cases in 2011 vs. 39 [29%] in 2012). The main indications for autologous transplants were multiple myeloma/plasma cell disorders (510; 39%), Hodgkin lymphoma (311; 24%), non-Hodgkin lymphoma (259; 20%), and solid tumors (163; 12%). Reduced intensity conditioning continued to show a progressive decrease over years (9.5% in 2011 vs. 7.9% in 2012), yet remained relatively low compared with contemporary practices in Europe published by EBMT. The vast majority (91%) of allo-HSCT source was from sibling donors with continued dominance of peripheral blood (64%) followed by bone marrow (33%).While umbilical cord blood transplants increased to 4% of allo-HSCT, matched unrelated donor remained underutilized and there was no haplo-identical transplant reported. Large centers with >50 HSCT/year, showed a continued increase in the total number of allo-HSCT over the past 2 years that may be related to capacity building issues and require further studies. Conclusion There is a discernable increase of HSCT rate in the EMRO region with a significant expansion in utilization of cord blood transplants and allogeneic peripheral blood-HSCT as a valuable source. However, further research of outcome data and the development of regional donor banks (cord blood and matched unrelated donors) may help to facilitate future planning to satisfy the escalating regional needs and augment collaboration within the EMBMT and globally.

AB - Objective/Background The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) group has accumulated over 31 years of data and experience in hematopoietic stem cell transplantation (HSCT), particularly in hemoglobinopathies, severe aplastic anemia, inherited metabolic and immune disorders, in addition to a wide array of hematologic malignancies unique to this region. A regional update in current HSCT trends is highly warranted. We studied the trends of HSCT activities in World Health Organization-Eastern Mediterranean (EMRO) region, surveyed by the EMBMT, between 2011 and 2012. Methods Retrospective analysis of the survey data mainly of cumulative number of transplants, types of transplants (autologous vs. allogeneic), types of conditioning such as myeloablative versus reduced intensity was conducted. Also, trends in leukemias, hemoglobinopathies, severe aplastic anemia, inherited bone marrow failure syndromes, amongst others were analyzed. Results Twenty-one teams from nine EMRO countries reported their data (100% return rate) to the EMBMT for the years 2011-2012, with a total of 3,546 first HSCT (1,670 in 2011; 1,876 in 2012). Allogeneic HSCT (allo-HSCT) represented the majority (62%) in both years. The main indications for allo-HSCT were acute leukemias (988; 46%), bone marrow failure syndromes (421, 20%), hemoglobinopathies (242; 11%), and immune deficiencies (157; 7%). There was a progressive increase in the proportions of chronic myeloid leukemia cases transplanted beyond first chronic phase (37 [7%] of all chronic myeloid leukemia cases in 2011 vs. 39 [29%] in 2012). The main indications for autologous transplants were multiple myeloma/plasma cell disorders (510; 39%), Hodgkin lymphoma (311; 24%), non-Hodgkin lymphoma (259; 20%), and solid tumors (163; 12%). Reduced intensity conditioning continued to show a progressive decrease over years (9.5% in 2011 vs. 7.9% in 2012), yet remained relatively low compared with contemporary practices in Europe published by EBMT. The vast majority (91%) of allo-HSCT source was from sibling donors with continued dominance of peripheral blood (64%) followed by bone marrow (33%).While umbilical cord blood transplants increased to 4% of allo-HSCT, matched unrelated donor remained underutilized and there was no haplo-identical transplant reported. Large centers with >50 HSCT/year, showed a continued increase in the total number of allo-HSCT over the past 2 years that may be related to capacity building issues and require further studies. Conclusion There is a discernable increase of HSCT rate in the EMRO region with a significant expansion in utilization of cord blood transplants and allogeneic peripheral blood-HSCT as a valuable source. However, further research of outcome data and the development of regional donor banks (cord blood and matched unrelated donors) may help to facilitate future planning to satisfy the escalating regional needs and augment collaboration within the EMBMT and globally.

KW - Conditioning

KW - EMRO

KW - Hematopoietic stem cell transplantation

KW - Stem cell source

UR - http://www.scopus.com/inward/record.url?scp=84962291093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962291093&partnerID=8YFLogxK

U2 - 10.1016/j.hemonc.2015.09.002

DO - 10.1016/j.hemonc.2015.09.002

M3 - Article

C2 - 26452331

AN - SCOPUS:84962291093

VL - 8

SP - 167

EP - 175

JO - Hematology/ Oncology and Stem Cell Therapy

JF - Hematology/ Oncology and Stem Cell Therapy

SN - 1658-3876

IS - 4

ER -